Register
Pink Sheets Markets Today:
Aug 22, 2016 total dollar volume
$315,836,217
Author:
By Boyan Angelov
Nov 25, 2014

Aethlon Medical, Inc. (AEMD) Soars On Positive Evaluation. Delivers Further News

Aethlon Medical, Inc. (AEMD) ended last week with good momentum which the ticker managed to keep going into this week. AEMD stock gained 23.46% in price on Friday and a further 8.83% at the beginning of this trading week on a 52-week high volume of 40,466,001 shares trading hands.

The penny stock's success came about after its Hemopurifier® bio-filtration device was listed as “one of the 25 best inventions of 2014” by Time Magazine. AEMD talked about this high evaluation in a press release published on November 21.Aethlon Medical, Inc. stock chart

Earlier today, the company issued a press release, informing that an Ebola patient who was treated with the Hemopurifier® therapy had been discharged from Frankfurt University Hospital in Germany. The person in question is a Ugandan physician who was infected with the disease while treating patients in Sierra Leone. Although we cannot know what other treatment lead to curing the disease, we do know that AEMD's Hemopurifier® therapy was also utilized.

Before receiving further details on the matter, investors should put long term evaluation as a priority. It is by no means uncommon for penny stocks to spike up on increased interest due to a certain event or news item. Excitement can play a leading role in the movement of a stock up and down the charts. However, the financial disposition of a company is what keeps it going in the long run. AEMD has reported the following numbers for the third fiscal quarter ended September 30, 2014:

  • Cash: $526.1 thousand
  • Total current assets: $892.1 thousand
  • Total current liabilities: $3.3 million
  • Revenues: $479 thousand
  • Net loss: $888.1 thousand

The company's cash and asset base has gone down in the past quarter. At the same time, the huge amount of accumulated liabilities has also decreased significantly. AEMD has still ended at a high net loss, though much lower than in the previous period.

As of September 30, the company had convertible notes payable in the total amount of $1,473,941. For the same period, there were a total of 82,782,621 warrants exercisable. AEMD used share issuance to pay for services provided on two occasions. One instance was for an aggregate of 359,956 shares of common stock at a price of $0.14 per share and the other was for 390,301 shares of restricted common stock at price per share of $0.19.

AEMDA total of 1,937,505 shares of restricted common stock have been issued for note conversion in the past quarter. AEMD issued 2,673,231 shares of restricted common stock through the exercise of eight warrants in the total amount of $259,474, held by four investors. The company has sold units for proceeds of $90 thousand to three accredited investors. The units consist of a total aggregate of 974,982 shares of common stock and warrants to acquire up to an aggregate of 487,491 shares of common stock.

The issuance and conversion have continued through the current quarter. As it stands, investors should do their due diligence and carefully weigh out the risks before making an investment in AEMD stock.

Average Reader Price Target For AEMD:

Going Down!
0.2126

What price do you think this stock will go to?

Reader Valuation Chart

Article Comments:


Comment: